
    
      This study is an international, multicentre, prospective, fixed-time point (optional)
      randomisation for two arms ([A] 'dose of rtPA' and [B] 'level of BP control'), open-label,
      blinded endpoint (PROBE) controlled trial that involved 4587 patients (3310 for rtPA arm
      {recruitment completed in August 2015} and 2227 for BP arm {recruitment completed in April
      2018} with 939 overlap) with acute ischaemic stroke recruited from over 100+ Clinical Centres
      from Australia, Asia, Europe and South America.
    
  